{
    "id": 20708,
    "cites": 44,
    "cited_by": 1,
    "reference": [
        "Acemoglu, Daron, and Amy Finkelstein. 2008. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Input and Technology Choices in Regulated Industries: Evidence from the Health Care Sector.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Political Economy 116 (5): 837\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c80.",
        "Alpert, Abby. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Anticipatory Effects of Medicare Part D on Drug Utilization.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working Paper, April.",
        "Anderson, Michael L., Carlos Dobkin, and Tal Gross. 2014. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Effect of Health Insurance on Emergency Department Visits: Evidence from an Age-Based Eligibility Threshold.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Review of Economics and Statistics 96 (1): 189\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c95.",
        "Arrow, Kenneth J. 1963. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Uncertainty and the Welfare Economics of Medical Care.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The American Economic Review 53 (5): 941\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c73.",
        "Blume-Kohout, Margaret E, and Neeraj Sood. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 97 (January): 327\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c36.",
        "Briesacher, Becky A, Yanfang Zhao, Jeanne M Madden, Fang Zhang, Alyce S Adams, Jennifer Tjia, Dennis Ross-Degnan, Jerry H Gurwitz, and Stephen B Soumerai. 2011. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medicare Part D and Changes in Prescription Drug Use and Cost Burden: National Estimates for the Medicare Population, 2000 to 2007.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Medical Care 49 (9): 834\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c41.",
        "Carrera, Mariana, Dana Goldman, and Geoffrey Joyce. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Heterogeneity in Cost-Sharing and Cost-Sensitivity, and the Role of the Prescribing Physician.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d NBER Working Paper Series, no. 19186 (June).",
        "Chalkley, Martin, and James M. Malcomson. 1998. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Contracting for Health Services When Patient Demand Does Not Reflect Quality.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 17 (1): 1\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c19.",
        "Charlson, Mary E., Peter Pompei, Kathy L. Ales, and C.Ronald MacKenzie. 1987. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Chronic Diseases 40 (5): 373\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c83.",
        "Chay, Kenneth Y., Daeho Kim, and Shailender Swamina. 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medicare, Hospital Utilization and Mortality: Evidence from the Program\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Origins.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working Paper.",
        "Congressional Budget Office (CBO). 2009. Promotional Spending for Prescription Drugs. http://www.cbo.gov/sites/default/files/12-02-drugpromo_brief.pdf.",
        "Dalen, Dag Morten, Enrico Sorisio, and Steinar Strom. 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Choosing Among Competing Blockbusters: Does the Identity of the Third-Party Payer Matter for Prescribing Doctors?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working Paper, October.",
        "Ellis, Randall P., and Thomas G. McGuire. 1986. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Provider Behavior under Prospective Reimbursement.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 5 (2): 129\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c51.",
        "Engelberg, Joseph, Christopher A. Parsons, and Nathan Tefft. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093First, Do No Harm: Financial Conflicts in Medicine.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working Paper, January.",
        "Federman, Alex D. 2004. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Don\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2t Ask, Don&apos;t Tell: The Status of Doctor-Patient Communication about Health Care Costs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Archives of Internal Medicine 164 (16): 1723\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c24.",
        "Feldstein, Martin S. 1970. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Rising Price of Physicians\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 Services.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Review of Economics and Statistics 52 (2): 121\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c33.",
        "Grembi, Veronica, Tommaso Nannicini, and Ugo Troiano. 2011. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Do Fiscal Rules Matter? A Difference-in-Discontinuities Design.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working Paper, February.",
        "Ho, Kate, and Ariel Pakes. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Hospital Choices, Hospital Prices and Financial Incentives to Physicians.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d NBER Working Paper Series, no. 19333 (August).",
        "Iizuka, Toshiaki. 2007. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Experts\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 Agency Problems: Evidence from the Prescription Drug Market in Japan.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Rand Journal of Economics 38 (3): 844\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c62.",
        "\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Physician Agency and Adoption of Generic Pharmaceuticals.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review 102 (6): 2826\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c58.",
        "Kaestner, Robert, and Nasreen Khan. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medicare Part D and Its Effect on the Use of Prescription Drugs and Use of Other Health Care Services of the Elderly.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Policy Analysis and Management 31 (2): 253\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c79.",
        "Kaestner, Robert, Cuiping Long, and G. Caleb Alexander. 2014. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Effects of Prescription Drug Insurance on Hospitalization and Mortality: Evidence from Medicare Part D.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d NBER Working Paper Series, no. 19948 (February).",
        "Ketcham, Jonathan D, and Kosali I Simon. 2008. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medicare Part D\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Effects on Elderly Patients&apos; Drug Costs and Utilization.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The American Journal of Managed Care 14 (11 Suppl): SP14\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 22.",
        "Lee, David S, and Thomas Lemieux. 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Regression Discontinuity Designs in Economics.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Literature 48 (2): 281\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c355.",
        "Lichtenberg, Frank R, and Shawn X Sun. 2007. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Impact of Medicare Part D on Prescription Drug Use By the Elderly.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs (Project Hope) 26 (6): 1735\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c44.",
        "Liu, Frank Xiaoqing, G Caleb Alexander, Stephanie Y Crawford, A Simon Pickard, Donald Hedeker, and Surrey M Walton. 2011. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Impact of Medicare Part D on Out-of-Pocket Costs for Prescription Drugs, Medication Utilization, Health Resource Utilization, and Preference-Based Health Utility Utility.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Services Research 46 (4): 1104\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c23.",
        "Liu, Ya-Ming, Yea-Huei Kao Yang, and Chee-Ruey Hsieh. 2009. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Financial Incentives and Physicians\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 Prescription Decisions on the Choice between Brand-Name and Generic Drugs: Evidence from Taiwan.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 28 (2): 341\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c49.",
        "Lu, Fangwen. 2014. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Insurance Coverage and Agency Problems in Doctor Prescriptions: Evidence from a Field Experiment in China.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 106 (January): 156\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c67.",
        "Lundin, Douglas. 2000. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Moral Hazard in Physician Prescription Behavior.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 19 (5): 639\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c62.",
        "McCrary, Justin. 2008. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Manipulation of the Running Variable in the Regression Discontinuity Design: A Density Test.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Econometrics 142 (2). Elsevier: 698\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c714.",
        "Nguyen, Ha. 2011. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Principal-Agent Problems in Health Care: Evidence from Prescribing Patterns of Private Providers in Vietnam.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Policy and Planning 26 (suppl_1): i53\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 62.",
        "Pauly, Mark. 1980. Doctors and Their Workshops: Economic Models of Physician Behavior. NBER Books. National Bureau of Economic Research, Inc.",
        "Roth, Martin S. 1996. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patterns in Direct-to-Consumer Prescription Durg Print Advertising and Their Public Policy Implications.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Policy & Marketing 15 (1): 63\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c75.",
        "Sacks, Daniel W. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Physician Agency , Compliance , and Patient Welfare\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u00af: Evidence from Anti-Cholesterol Drugs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working Paper.",
        "Stern, Scott, and Manuel Trajtenberg. 1998. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Empirical Implications of Physician Authority in Pharmaceutical Decisionmaking.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d NBER Working Paper Series, no. 6851 (December).",
        "The Henry J. Kaiser Family Foundation. 2003. The Medicare Prescription Drug Benefit Fact Sheet.",
        "\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d. 2006. The Medicare Prescription Drug Benefit Fact Sheet.",
        "\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d. 2007a. The Medicare Prescription Drug Benefit Fact Sheet.",
        "\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d. 2007b. Medicare Spending and Financing Fact Sheet.",
        "\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d. 2010. The Medicare Prescription Drug Benefit Fact Sheet.",
        "Vakratsas, Demetrios, and Tim Ambler. 1999. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093How Advertising Works: What Do We Really Know?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Marketing 63 (1): 26\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c43.",
        "Weisbrod, Burton A. 1991. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Health Care Quadrilemma: An Essay on Technological Change, Insurance, Quality of Care, and Cost Containment.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Literature 29 (2): 523\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c52.",
        "Yin, Wesley, Anirban Basu, James X Zhang, Atonu Rabbani, David O Meltzer, and G Caleb Alexander. 2008. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Effect of the Medicare Part D Prescription Benefit on Drug Utilization and Expenditures.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Annals of Internal Medicine 148 (3): 169\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c77.",
        "Yip, Winnie C. 1998. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Physician Response to Medicare Fee Reductions: Changes in the Volume of Coronary Artery Bypass Graft (CABG) Surgeries in the Medicare and Private Sectors.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 17 (6): 675\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c99."
    ]
}